We recently published a list of 10 Hot Biotech Stocks Under $5. In this article, we are going to take a look at where Cardiff ...
Its main drug, onvansertib, is an oral Polo-like Kinase 1 (PLK1) inhibitor targeting KRAS-mutated colorectal cancer (mCRC) and other tumors. The company has shown promising clinical results and ...
Peer ReviewDownload a summary of the editorial decision process including editorial decision letters, reviewer comments and author responses to feedback. Polo-like kinase 1 (PLK1) is a conserved ...
CDK1/Cyclin B interacts with Aurora kinase A to enhance its phosphorylation and activation of PLK1. Aurora kinase A activity is inhibited by BRCA1. PLK1 induces CDC25C activation and WEE1 degradation ...
2023). Steegmaier et al., 2007 reported the discovery of BI2536, a potent and selective small molecule inhibitor of Polo-like kinase 1 (PLK1). BI2536 is the first compound to induce all features ...
BERKELEY HEIGHTS, N.J., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. ("Cyclacel") (NASDAQ: CYCC, NASDAQ: CYCCP), a biopharmaceutical company that ...
What Is Mevalonate Kinase Deficiency? Mevalonate kinase deficiency (MKD) is a disease that runs in families. A problem with your immune system causes attacks of fever and symptoms like swollen ...
This study provides a convincing explanation for why HIV-1 Vif causes a qualitatively different cell cycle arrest to its accessory gene counterpart Vpr. The authors use elegant time-dependent ...
The study by Pudlowski et al. shows that a previously-identified protein complex, composed of delta- and epsilon-tubulin together with TEDC1 and TEDC2, functions in generating centriolar triplet ...
Multiple novel targeted therapies are being investigated for treating CMML, including Janus kinase-signal transducer and activator of transcription (JAK/STAT) inhibitors, polo-like kinase 1 (PLK1 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback